Medication info
Pregabalin Capsule 150 mg (Pregabalin)

Pregabalin Capsule 150 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›150mg / 1 capsule
Manufacturer / importer
Hwanin Pharmaceutical Co., Ltd.
Appearance
Hard capsules with a white upper part and white lower part containing a white or light yellow powder
Packaging
For domestic use - 30 capsules/bottle, For domestic use - 100 capsules/bottle, For export - 30 capsules/box [(10 capsules/PTP × 3)]
Approval status
Active

MFDS item code 201109260 · Approved 2011.10.27 · Insurance code 657202340

Summary

Main use
Neuropathic pain, adjunctive therapy for partial-onset seizures in epilepsy, treatment of fibromyalgia
Who takes it
Adults · Children
Adult dose
This medication is administered orally, regardless of food, with the total daily dose of pregabalin divided into 2 doses. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (Refer to ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (Refer to ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg ∼ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys unchanged. Since the clearance of this medication is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained using the above equation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30 -<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15 -<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a : The total daily dose (mg/day) should be administered in divided doses as specified in the administration schedule. b : The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended. Adolescent patients aged 12 ∼ 17 years: Administration is not recommended.

Ingredients

Manufacturer
Hwanin Pharmaceutical Co., Ltd.

Efficacy & effects

Neuropathic pain, adjunctive therapy for partial-onset seizures in epilepsy, treatment of fibromyalgia

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used for the relief of peripheral and central neuropathic pain in adults. Additionally, it serves as an adjunctive treatment for partial seizures in epilepsy patients, effective whether or not there are secondary generalized symptoms. Moreover, it helps improve chronic pain associated with fibromyalgia. In other words, it is used to alleviate the symptoms of neuropathic pain, epilepsy, and fibromyalgia.

How to take

Adult dose

This medication is administered orally, regardless of food, with the total daily dose of pregabalin divided into 2 doses. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (Refer to ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (Refer to ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg ∼ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys unchanged. Since the clearance of this medication is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained using the above equation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30 -<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15 -<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a : The total daily dose (mg/day) should be administered in divided doses as specified in the administration schedule. b : The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended. Adolescent patients aged 12 ∼ 17 years: Administration is not recommended.

Precautions

This medication may increase the risk of suicidal thoughts or behavior, so it is important to closely monitor any mood changes or unusual behavior during treatment. Patients with allergies to any component of this drug should not take it. Patients with diabetes may experience weight gain after taking this medication, which may necessitate adjustments in their blood sugar control medications. If allergic reactions such as angioedema occur, the medication should be stopped immediately and the healthcare provider should be informed. Older adults are at risk of falls or injury due to dizziness or drowsiness, hence caution is particularly advised during the initial phase of treatment. Vision blur or changes in eyesight may occur; if these symptoms develop, consideration should be given to discontinuing the drug. Caution is required when stopping other antiepileptic drugs while taking this medication. Discontinuing this medication suddenly can lead to withdrawal symptoms such as insomnia, headache, and anxiety, so consultation with a healthcare provider is necessary. There is a risk of drug abuse, so patients with a history of substance abuse should definitely consult their healthcare provider before use. Patients with impaired kidney function may require dosage adjustments. Patients with heart disease should use this medication cautiously, and particularly those with congestive heart failure should consult with their healthcare provider. Taking this medication with opioid analgesics can increase central nervous system depressant effects, so caution is needed. Patients with respiratory or neurological diseases, kidney disorders, and older adults may have a risk of severe respiratory depression, so dose adjustment may be necessary. Pregnant women are advised not to take this medication during early pregnancy due to the risk of fetal malformations, and women of childbearing age should use effective contraception. Lactating women should consider stopping breastfeeding or the medication itself, as this drug can be transmitted through breast milk. This medication can cause dizziness and drowsiness; therefore, caution should be exercised when driving or operating machinery after taking it. Severe skin reactions may rarely occur, and if any skin abnormalities appear, the medication should be stopped immediately and the healthcare provider should be informed. Overdose may lead to confusion, drowsiness, and depression, and appropriate treatment should be sought immediately at a medical institution. Keep this medicine out of reach of children and do not transfer it to another container for safety.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal mood and behavior changes
  • angioedema
  • facial edema
  • periorbital edema
  • upper airway edema
  • dizziness
  • drowsiness
Show 180 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • sadness
  • suicidal thoughts
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • decreased respiratory function
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • abdominal distension
  • excessive salivation
  • gastroesophageal reflux
  • decreased oral sensation
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle spasms
  • arthralgia
  • back pain
  • limb pain
  • cervical spasm
  • joint swelling
  • myalgia
  • muscle cramps
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • reduced urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • breast discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling intoxicated
  • altered sensation
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • increased serum creatinine
  • decreased white blood cell count
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • feelings of contentment
  • decreased libido
  • depersonalization
  • sexual hyperesthesia
  • restlessness
  • mood swings
  • emotional dullness
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulse control difficulties
  • emotional blunting
  • ataxia
  • abnormal motor coordination
  • balance disorders
  • amnesia
  • attention deficits
  • memory impairment
  • trembling
  • dysarthria
  • sensory abnormalities
  • sensory loss
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorder
  • tonic-clonic seizures
  • reduced reflexes
  • abnormal movements
  • psychomotor agitation
  • positional dizziness
  • perceptual hypersensitivity
  • burning sensation
  • action tremors
  • syncope
  • confusion
  • motor retardation
  • olfactory disturbances
  • taste loss
  • writing difficulties
  • diplopia
  • hyperacusis
  • first-degree AV block
  • tachycardia
  • homogenous bradycardia
  • homogenous tachycardia
  • homogenous arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • keratitis
  • pulmonary edema
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • confused state
  • agitation
  • restlessness
  • worsening of convulsions
  • ataxia
  • dysphasia
  • bloody stools
  • increased BUN
  • urinary difficulties
  • tinnitus
  • skin disorders

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. It is advisable to maintain a storage temperature between 15 and 30 degrees Celsius. Proper storage will help preserve the drug's effectiveness for a longer period.

Appearance and packaging

Appearance

Hard capsules with a white upper part and white lower part containing a white or light yellow powder

Package unit

For domestic use - 30 capsules/bottle, For domestic use - 100 capsules/bottle, For export - 30 capsules/box [(10 capsules/PTP × 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.